Abbott Laboratories (ABT)
Abbott (ABT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ABT's FreeStyle Libre 3 Plus Now Available in Canada: Stock to Rise?
Abbott debuts FreeStyle Libre 3 Plus in Canada, enhancing diabetes care with the world's smallest glucose sensor.
Should You Buy Abbott Stock At $135?
Abbott Laboratories (NYSE:ABT) has greatly exceeded the broader S&P 500 index this year, with its stock price increasing by 18% compared to the S&P 500's 6% rise. This strong performance is due to the company's solid quarterly results and positive future forecasts.
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Abbott (ABT) stood at $134.11, denoting a -1.58% move from the preceding trading day.
Abbott (ABT) Upgraded to Buy: Here's What You Should Know
Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Abbott Sees Upside on Diagnostics Growth, FreeStyle Libre Expansion
ABT stock surges 21.7% year to date on CGM sales growth and robust diagnostics demand, even as FX and macro risks weigh on forecasts.
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott Labs: Proactive, Adaptive, Solid
Abbott's proactive leadership and diversified business model help it navigate macro challenges and market volatility effectively. Strong Q1 performance in Nutrition, Medical Devices, and Vascular segments offsets weakness in Diagnostics and China sales, showcasing resilience and adaptability. Management's focus on gross margin expansion, cost-saving initiatives, and shareholder-friendly policies like dividend increases support long-term value.
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Abbott (ABT) stood at $133.67, denoting a -2.71% move from the preceding trading day.
Best Dividend Kings: June 2025
Dividend Kings have underperformed the S&P 500 year-to-date, but 26 are outperforming SPY in 2025, with 32 posting positive returns. Dividend growth remains healthy, with four recent increases and a collective 2025 growth rate of 5.19%, despite some downward earnings revisions. Seventeen Dividend Kings appear undervalued and offer long-term annualized expected returns of at least 10%, based on Dividend Yield Theory analysis.
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
